Reshape Lifesciences Inc (STU:24O0)

€ 0.615 0 (0%) Market Cap: 3.67 Mil Enterprise Value: 2.59 Mil PE Ratio: 0 PB Ratio: 1.02 GF Score: 36/100

Q1 2024 ReShape Lifesciences Inc Earnings Call Transcript
May 15, 2024

Earnings
Q4 2023 ReShape Lifesciences Inc Earnings Call Transcript
Apr 01, 2024

Earnings
Q3 2023 ReShape Lifesciences Inc Earnings Call Transcript
Nov 08, 2023

€0.615

Earnings
Q2 2023 ReShape Lifesciences Inc Earnings Call Transcript
Aug 07, 2023

€1.22 (-1.61%)

Earnings
ReShape Lifesciences Inc at OTC Markets Life Science Investor Forum Transcript
Jun 22, 2023
Q1 2023 ReShape Lifesciences Inc Earnings Call Transcript
May 15, 2023

€2.06 (-0.96%)

Earnings
Q4 2022 ReShape Lifesciences Inc Earnings Call Transcript
Apr 25, 2023

€2.26 (-3.42%)

Earnings
Q3 2022 ReShape Lifesciences Inc Earnings Call Transcript
Nov 14, 2022

€10.24 (-2.24%)

Earnings
Q2 2022 ReShape Lifesciences Inc Earnings Call Transcript
Aug 15, 2022

€23.93 (+7.87%)

Earnings
Q1 2022 ReShape Lifesciences Inc Earnings Call Transcript
May 23, 2022

€37.14 (-1.93%)

Earnings
Q4 2021 ReShape Lifesciences Inc Earnings Call Transcript
Mar 28, 2022

€62 (+3.77%)

Earnings
ReShape Lifesciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021
Q4 2019 Obalon Therapeutics Inc Earnings Call Transcript
Feb 27, 2020

Earnings
Q3 2019 Obalon Therapeutics Inc Earnings Call Transcript
Nov 08, 2019

Earnings
Q2 2019 Obalon Therapeutics Inc Earnings Call Transcript
Jul 24, 2019

Earnings
Q4 2018 Obalon Therapeutics Inc Earnings Call Transcript
Feb 22, 2019

Earnings

Q4 2018 Obalon Therapeutics Inc Earnings Call Transcript

Feb 22, 2019 / 01:30PM GMT

Transcript 10-K8-K

Operator

Good day, ladies and gentlemen, and welcome to the Obalon Therapeutics Fourth Quarter and Full Year 2018 Financial Results Call. (Operator Instructions) As a reminder, today's call will be recorded.

I would now like to turn the call over to Bill Plovanic, Chief Financial Officer for Obalon, you may begin.

William John Plovanic

Obalon Therapeutics, Inc. - CFO & Secretary

Thank you. Good morning, and welcome to Obalon Therapeutics Fourth Quarter and Full Year 2018 Financial Results Conference Call. With me on today's call is Dr. Kelly Huang, President and Chief Executive Officer of Obalon.

This morning, the company issued a press release detailing our financial results for the 3 and 12 months ended December 31, 2018. This release can be accessed through the Investor Relations section of the Obalon website at obalon.com. You can also access the webcast of this call from there.

Before we get started, I would like to remind everyone that many statements made on today's conference call that expresses a belief, expectation, projection

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.